1.4895
price up icon1.02%   0.0195
 
loading
Opko Health Inc stock is traded at $1.4895, with a volume of 1.82M. It is up +1.02% in the last 24 hours and down -3.57% over the past month. OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
See More
Previous Close:
$1.47
Open:
$1.48
24h Volume:
1.82M
Relative Volume:
0.48
Market Cap:
$995.74M
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-7.8395
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
+0.34%
1M Performance:
-3.57%
6M Performance:
-0.34%
1Y Performance:
+48.95%
1-Day Range:
Value
$1.47
$1.51
1-Week Range:
Value
$1.4501
$1.52
52-Week Range:
Value
$0.8601
$1.76

Opko Health Inc Stock (OPK) Company Profile

Name
Name
Opko Health Inc
Name
Phone
305-575-4181
Name
Address
4400 BISCAYNE BLVD., MIAMI, FL
Name
Employee
3,930
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
OPK's Discussions on Twitter

Compare OPK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
OPK
Opko Health Inc
1.4843 995.74M 711.41M -133.73M -199.99M -0.19
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
571.46 218.59B 42.37B 6.14B 7.78B 15.95
Diagnostics & Research icon
DHR
Danaher Corp
243.71 175.15B 23.74B 3.89B 4.98B 5.24
Diagnostics & Research icon
A
Agilent Technologies Inc
152.95 43.00B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
204.30 36.60B 15.32B 1.41B 1.96B 7.62
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
427.31 34.77B 3.84B 866.24M 792.60M 10.37

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-29-23 Upgrade Barrington Research Mkt Perform → Outperform
Dec-15-22 Initiated H.C. Wainwright Buy
Jan-24-22 Downgrade Barrington Research Outperform → Mkt Perform
Jun-21-21 Initiated Ladenburg Thalmann Buy
Nov-25-19 Initiated Piper Jaffray Overweight
Mar-02-18 Downgrade JP Morgan Neutral → Underweight
Sep-14-17 Downgrade JP Morgan Overweight → Neutral
Jun-21-16 Reiterated Standpoint Research Buy
Jun-03-16 Initiated Standpoint Research Buy
Mar-31-16 Reiterated Barrington Research Outperform
Oct-16-15 Initiated JP Morgan Overweight
Sep-11-15 Downgrade Jefferies Buy → Hold
Mar-03-15 Downgrade Oppenheimer Outperform → Perform
May-12-14 Reiterated Oppenheimer Outperform
Mar-14-14 Initiated Oppenheimer Outperform
Nov-13-13 Reiterated Ladenburg Thalmann Buy
May-30-13 Reiterated Ladenburg Thalmann Buy
Oct-22-12 Initiated Barrington Research Outperform
Dec-01-11 Reiterated Ladenburg Thalmann Buy
Jul-14-11 Initiated Ladenburg Thalmann Buy
View All

Opko Health Inc Stock (OPK) Latest News

pulisher
Jan 20, 2025

OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Finance

Jan 20, 2025
pulisher
Jan 20, 2025

12 Stocks Under $5 With Biggest Upside Potential - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

Opko health CEO Phillip Frost buys $220,425 in common stock - MSN

Jan 19, 2025
pulisher
Jan 18, 2025

OPKO Health : Immediate Report -January 18, 2025 at 06:29 am EST - Marketscreener.com

Jan 18, 2025
pulisher
Jan 18, 2025

BioReference faces $704,349 fine for medically unnecessary blood tests - MSN

Jan 18, 2025
pulisher
Jan 17, 2025

Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

BioReference Health and OPKO Health Agree to Pay $704,349 to Settle Allegations that they Billed the - U.S. Politics Today

Jan 17, 2025
pulisher
Jan 17, 2025

Opko health CEO Phillip Frost buys $220,425 in common stock By Investing.com - Investing.com Nigeria

Jan 17, 2025
pulisher
Jan 17, 2025

BioReference Health, OPKO Health Settle False Claims Violations - Bloomberg Law

Jan 17, 2025
pulisher
Jan 16, 2025

Barclays PLC Acquires 329,870 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Opko health CEO Phillip Frost buys $740,850 in stock By Investing.com - Investing.com Canada

Jan 15, 2025
pulisher
Jan 15, 2025

Opko health CEO Phillip Frost buys $740,850 in stock - Investing.com India

Jan 15, 2025
pulisher
Jan 15, 2025

OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $740,000.00 in Stock - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Opko Health Engages Investors at J.P. Morgan Conference - TipRanks

Jan 15, 2025
pulisher
Jan 15, 2025

OPKO Health (NASDAQ:OPK) Stock Rating Lowered by StockNews.com - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk - Simply Wall St

Jan 14, 2025
pulisher
Jan 09, 2025

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 09, 2025
pulisher
Jan 08, 2025

Opko Health stock buy rating reaffirmed, steady target on clinical trial - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

OPKO Health's (OPK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

OPKO Health (NASDAQ:OPK) Upgraded by StockNews.com to "Hold" Rating - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr - GlobeNewswire

Jan 07, 2025
pulisher
Jan 07, 2025

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

OPKO Health (NASDAQ:OPK) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Jan 06, 2025
pulisher
Dec 31, 2024

OPKO Health, Inc. (NASDAQ:OPK) Stake Cut by Geode Capital Management LLC - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

3 Stocks That Wall Street Insiders Can't Stop Buying - MSN

Dec 31, 2024
pulisher
Dec 30, 2024

3 Stocks That Wall Street Insiders Can’t Stop Buying - sharewise

Dec 30, 2024
pulisher
Dec 30, 2024

Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail

Dec 30, 2024
pulisher
Dec 30, 2024

OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 14.0% in December - MarketBeat

Dec 30, 2024
pulisher
Dec 26, 2024

OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by State Street Corp - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

OPKO Health (NASDAQ:OPK) Downgraded to Sell Rating by StockNews.com - MarketBeat

Dec 26, 2024
pulisher
Dec 20, 2024

OPKO Health delivers 57% gain after January Fair Value signal flags undervaluation - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

Esoteric Testing Market is Set to Experience a Revolutionary Growth | Labcorp, Quest Diagnostics, OPKO Health - openPR

Dec 20, 2024
pulisher
Dec 19, 2024

Connected Drug Delivery Devices Market is Dazzling Worldwide - openPR

Dec 19, 2024
pulisher
Dec 18, 2024

OPKO Health (NASDAQ:OPK) Raised to Hold at StockNews.com - MarketBeat

Dec 18, 2024
pulisher
Dec 14, 2024

OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $198,750.00 in Stock - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Phillip Frost Buys Handful Of Shares In OPKO Health - Simply Wall St

Dec 14, 2024
pulisher
Dec 13, 2024

Opko health CEO Phillip Frost buys $199,375 in stock By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 13, 2024

Opko health CEO Phillip Frost buys $199,375 in stock - Investing.com

Dec 13, 2024
pulisher
Dec 13, 2024

Opko Health stock hits 52-week high of $1.75 amid growth - Investing.com Canada

Dec 13, 2024

Opko Health Inc Stock (OPK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Opko Health Inc Stock (OPK) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 15 '25
Buy
1.48
500,000
740,850
213,036,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 13 '24
Buy
1.59
125,000
199,375
212,536,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 11 '24
Buy
1.56
500,000
781,050
212,411,477
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 29 '24
Buy
1.53
199,072
305,376
211,911,477
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 22 '24
Buy
1.59
100,000
159,000
211,712,405
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 14 '24
Buy
1.62
100,000
161,980
211,612,405
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 08 '24
Buy
1.50
280,183
421,535
211,512,405
$166.63
price up icon 4.98%
diagnostics_research LH
$243.91
price up icon 2.25%
$140.67
price up icon 3.11%
diagnostics_research WAT
$414.87
price up icon 2.69%
diagnostics_research MTD
$1,318.49
price up icon 1.83%
$424.89
price up icon 1.28%
Cap:     |  Volume (24h):